{"title":"Invasive pneumococcal disease caused by CO2-dependent Streptococcus pneumoniae serotype 24F sequence type 162: A case report","authors":"Takahiko Niwa , Takehisa Matsumoto , Misako Ohkusu , Naruhiko Ishiwada , Kazunori Fukushima , Suguru Hiramoto , Azusa Uchida , Katsuhiko Tsunekawa , Kiyohiro Oshima , Takao Kimura","doi":"10.1016/j.jiac.2025.102653","DOIUrl":null,"url":null,"abstract":"<div><div>We report the case of a man in his 70s who developed invasive pneumococcal disease (IPD) caused by CO<sub>2</sub>-dependent <em>Streptococcus pneumoniae</em>. He was admitted with suspected pneumonia based on chest X-ray and computed tomography imaging findings. Ceftriaxone treatment was initiated following the collection of sputum samples and two sets of blood cultures. The antimicrobial treatment was then changed to sulbactam/ampicillin (SBT/ABPC) because urine pneumococcal antigen testing performed on admission was positive. The following day, CO<sub>2</sub>-dependent <em>S. pneumoniae</em> was isolated from the blood cultures and sputum sample, leading to a diagnosis of IPD. The patient continued SBT/ABPC treatment (6 g/day) but remained febrile and died 4 days after admission. Serotyping and whole-genome sequence analysis of the isolate revealed that it was serotype 24F and sequence type (ST) 162. A c.536C > T mutation was identified in <em>murF</em> of the isolate compared with <em>S. pneumoniae</em> Spain9V-3. The isolation of CO<sub>2</sub>-dependent <em>S. pneumoniae</em> serotype 24F ST162 from pediatric patients in Japan was recently reported. However, to the best of our knowledge, this is the first reported IPD case in an elderly patient caused by CO<sub>2</sub>-dependent <em>S. pneumoniae</em> serotype 24F ST162. Thus, even in adults with IPD, caution should be exercised going forward.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 4","pages":"Article 102653"},"PeriodicalIF":1.9000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1341321X25000509","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
We report the case of a man in his 70s who developed invasive pneumococcal disease (IPD) caused by CO2-dependent Streptococcus pneumoniae. He was admitted with suspected pneumonia based on chest X-ray and computed tomography imaging findings. Ceftriaxone treatment was initiated following the collection of sputum samples and two sets of blood cultures. The antimicrobial treatment was then changed to sulbactam/ampicillin (SBT/ABPC) because urine pneumococcal antigen testing performed on admission was positive. The following day, CO2-dependent S. pneumoniae was isolated from the blood cultures and sputum sample, leading to a diagnosis of IPD. The patient continued SBT/ABPC treatment (6 g/day) but remained febrile and died 4 days after admission. Serotyping and whole-genome sequence analysis of the isolate revealed that it was serotype 24F and sequence type (ST) 162. A c.536C > T mutation was identified in murF of the isolate compared with S. pneumoniae Spain9V-3. The isolation of CO2-dependent S. pneumoniae serotype 24F ST162 from pediatric patients in Japan was recently reported. However, to the best of our knowledge, this is the first reported IPD case in an elderly patient caused by CO2-dependent S. pneumoniae serotype 24F ST162. Thus, even in adults with IPD, caution should be exercised going forward.
期刊介绍:
The Journal of Infection and Chemotherapy (JIC) — official journal of the Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases — welcomes original papers, laboratory or clinical, as well as case reports, notes, committee reports, surveillance and guidelines from all parts of the world on all aspects of chemotherapy, covering the pathogenesis, diagnosis, treatment, and control of infection, including treatment with anticancer drugs. Experimental studies on animal models and pharmacokinetics, and reports on epidemiology and clinical trials are particularly welcome.